In patients with MM, it has been suggested that G-CSF prophylaxis should be administered to those who are undergoing treatment regimens associated with a neutropenia rate of over 50% (those that combine lenalidomide with doxorubicin and dexamethasone, with MP or with cyclophosphamide and dexamethasone). This evidence concerns the gene CSF3 and neutropenia.